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Animal models of migraine and
experimental techniques used to examine
trigeminal sensory processing
Andrea M. Harriott1,2, Lauren C. Strother3, Marta Vila-Pueyo3 and Philip R. Holland3*
Abstract
Background: Migraine is a common debilitating condition whose main attributes are severe recurrent headaches
with accompanying sensitivity to light and sound, nausea and vomiting. Migraine-related pain is a major cause of
its accompanying disability and can encumber almost every aspect of daily life.
Main body: Advancements in our understanding of the neurobiology of migraine headache have come in large
from basic science research utilizing small animal models of migraine-related pain. In this current review, we aim to
describe several commonly utilized preclinical models of migraine. We will discuss the diverse array of
methodologies for triggering and measuring migraine-related pain phenotypes and highlight briefly specific
advantages and limitations therein. Finally, we will address potential future challenges/opportunities to refine
existing and develop novel preclinical models of migraine that move beyond migraine-related pain and expand
into alternate migraine-related phenotypes.
Conclusion: Several well validated animal models of pain relevant for headache exist, the researcher should
consider the advantages and limitations of each model before selecting the most appropriate to answer the
specific research question. Further, we should continually strive to refine existing and generate new animal and
non-animal models that have the ability to advance our understanding of head pain as well as non-pain symptoms
of primary headache disorders.
Keywords: Pain, Migraine, Headache, Preclinical, Animal models, Electrophysiology, Translation
Background
Migraine is a debilitating condition whose main attributes
are severe recurrent headaches with accompanying sensitiv-
ity to light and sound, nausea and vomiting. It is a highly
prevalent and heterogeneous neurological disorder affecting
approximately 6% of men and 18% of women [1] and is
mediated by a combination of genetic [2] and environmen-
tal factors [3]. The pain associated with migraine is a major
cause of its accompanying disability and can incumber
almost every aspect of daily living [4, 5]. The disability asso-
ciated with migraine underscores the need for selective and
effective therapeutic tools. To that end, advancements in
the neurobiology of migraine headache have come, in large
part, from basic science research utilizing small animal
models of migraine-related pain [6, 7] (Fig. 1). The recent
development of new antibody drugs to treat migraine pain
[8, 9] and pipeline therapies in development [10] is a testa-
ment to the translational potential of the animal models of
migraine. Despite this, the complexity of migraine has been
an impediment to fully modeling the disorder in animals
and remains a major hurdle to overcome.
Several lines of evidence suggest that activation of
trigeminal nociceptors innervating meningeal tissues
including dural arteries and sinuses is central to the ini-
tiation of migraine pain [11]. Stimulation of these trige-
minovascular afferents in humans can reproduce
referred pain with qualitative similarity to migraine in
cephalic regions [12]. While the central mechanisms by
which trigeminovascular afferents are activated remains
ill defined, once activated, they likely release neuropep-
tides including calcitonin gene related peptide (CGRP),
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substance P, neurokinin A and pituitary adenylate
cyclase activating peptide (PACAP) in the dura, and cen-
trally in the brainstem [13–15]. Release of CGRP periph-
erally from nociceptive afferents may mediate additional
release of mast cell contents and other immune media-
tors [16]. Subsequent sensitization of trigeminovascular
afferents and central sensitization of second order neu-
rons in the trigeminal nucleus caudalis [17] are import-
ant component parts of migraine neurobiology that
animal models ultimately seek to reproduce [11]. In this
review, we aim to describe the current array of preclin-
ical models available to researchers in the field. The
diverse array of methodologies for triggering and meas-
uring migraine-related pain phenotypes will be discussed
and we will briefly highlight potential novel technologies
and genetic tools that we feel will have a significant im-
pact on preclinical migraine research in the next decade.
We also highlight some clinical correlates to the models
being studied, their emergence from clinical observation,
potential in therapeutic testing and the extrapolation of
their findings to the human experience of migraine.
Animal models of migraine focused on trigeminal sen-
sory processing have increased our mechanistic under-
standing of migraine pathobiology and have direct
implications for target identification and translational
research. Data from the models described has led to ad-
vances in drug therapy and a better comprehension of
the mechanisms of drugs and devices currently approved
for the treatment of migraine. Lastly, use of these
models increased our understanding of the complex
interplay of sex, environment and genetic influences on
pain processing and migraine pathobiology. In addition
to the following discussion, the reader is directed to sev-
eral highly relevant review articles that complement the
content herein [7, 18–22].
Modeling migraine pain in the animal -
experimental approaches
In-vitro application of inflammatory mediators to
dissociated meningeal afferents
Release of algogenic and inflammatory substances
including nitric oxide, CGRP, neurokinin A, substance P,
Fig. 1 Selected models for assessing trigeminal sensory processing relevant to headache. Trigeminal afferents arising in the trigeminal ganglion
(TG) convey sensory information from the intracranial and extracranial vasculature to the trigeminal nucleus caudalis (TNC). Second-order
ascending projections then relay this information to the thalamus in combination with projections to key brainstem and hypothalamic nuclei.
This pathway can be activated via mechanical (MS), electrical (ES) or chemical (CS) stimuli. Evoked activation of the trigeminovascular system can
then be recorded using a variety of methodologies including, in-vivo electrophysiology (in-vivo Ephys) or markers of neuronal activation (e.g. c-Fos) in
the TNC or alternate brain regions. A trigeminal ganglion-skull cavity in-vitro preparation (Hemi-skull Prep) has also been developed to preserve some
degree of trigeminal/meningeal interface. Alternatively, trigeminal afferents arising in the TG can be dissociated and studied in-vitro using in-vitro
electrophysiology (In-vitro Ephys). Finally, periorbital mechanical and thermal (TS) withdrawal thresholds can be assessed in the conscious behaving
rodent to model more accurately altered pain responses at the whole animal level
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prostaglandins, and cytokines in the meninges are
thought to influence the activation of trigeminovascular
afferents [13, 23–25]. Moreover, in addition to the abun-
dance of neuropeptide containing afferent terminals
[26–29] meningeal tissues have a rich supply of mast
cells. Mast cell degranulation may increase meningeal
concentrations of histamine, serotonin and bradykinin
further impacting trigeminovascular afferents [30–32].
The mechanisms of this trigeminovascular afferent
activation can be studied in-vitro using application of
these inflammatory substances to acutely dissociated or
cultured trigeminal neurons. This includes targeted
approaches using retrograde tracers from the dura mater
to ensure the selection of acutely dissociated meningeal
afferents. Electrophysiology techniques can then be
utilized to examine changes specific for meningeal affer-
ent excitability [33], ion channel modulation [34, 35]
and afferent responses to current or novel migraine
therapeutic targets [34], in the presence and absence
of inflammatory mediators. For example, results from
this model support inflammatory mediator-induced
sensitization of trigeminovascular afferent nerve ter-
minals via increases in tetrodotoxin resistant sodium
currents, decreases in calcium dependent potassium
currents, activation of a calcium dependent chloride
current and increases in intracellular calcium signal-
ing [35]. Furthermore, data from this model provided
evidence that sumatriptan, a 5-HT1B/1D receptor
agonist and migraine abortive drug, can inhibit
voltage-gated calcium currents and produce hyperpo-
larizing shifts in voltage-gated potassium currents in
meningeal afferents [34]. Importantly, given the gen-
der bias in migraine, specific sexually dimorphic re-
sponses have also been noted. Specifically, there was
a greater proportion of dural afferents sensitized by
inflammatory mediators in female as compared to
male rats which may reflect sex-differences in activa-
tion of intracellular second-messenger pathways.
There were also sex differences in active electro-
physiological properties of the action potential wave-
form in females as compared to males following
inflammatory mediator exposure suggesting differen-
tial inflammation induced modulation of voltage
gated ion channels [36]. Additionally, in-vitro tri-
geminal neuron cultures can be combined with gen-
etically modified animals (see Future Perspectives
section) to examine changes more specific to
migraine pathobiology. For example, trigeminal gan-
glion neurons isolated from mice expressing genetic
mutations responsible for familial hemiplegic mi-
graine (FHM) type 1 (R192Q mutation of the CACN
A1A gene) were used to examine calcium/calmodulin
dependent protein kinase II mediated increases in
purinergic signaling [37].
Despite these important observations and the high-
throughput nature of this model, there are several limi-
tations that need to be carefully considered. The acute
dissociation of ganglion neurons augments the distribu-
tion of proteins in the membrane and may cause some
nerve injury and alterations in neuronal excitability, with
important implications for migraine biology [38]. Add-
itionally, the isolated nature of this model that can pro-
vide excellent mechanistic focus on meningeal afferents,
also precludes the ability to study the interaction with
other neuronal and non-neuronal populations including
sympathetic and parasympathetic neurons and gangli-
onic satellite glial cells which may obfuscate extrapola-
tion of the data obtained with this in-vitro model to the
in-vivo environment. While such limitations are some-
what addressed in the adapted trigeminal ganglion-skull
cavity in-vitro preparation (hemi-skull preparation) that
attempts to preserve the hemi-dura, studies of meningeal
inflammation are difficult. Nonetheless, using the in-
vitro hemi-dura preparation, investigators were able to
show that electrical stimulation of the trigeminal gan-
glion and application of inflammatory mediators on the
dura increased meningeal CGRP release and produced
longer-lasting increases in prostaglandin E2 [39]. Fur-
thermore, in-vitro techniques are not commonly used to
examine chronic or repetitive application of inflamma-
tory substances over time. Therefore, the recurrent na-
ture of migraine cannot be studied using this model.
The observed findings, however, form an important basis
for the determination of potential novel mechanisms in
migraine-related pain and the in-vitro nature of the
model has important ethical advantages, allowing rela-
tively high throughput screening combined with a po-
tential reduction in animal use [40].
Direct electrical stimulation of trigeminal neurons in-vivo
There are currently three principal migraine models
used to directly stimulate trigeminal neurons in-vivo.
These models have been improved overtime to lessen
their invasiveness and allow for chronic experimentation
[18]. The first involves electrical stimulation of the tri-
geminal ganglion, the second electrical stimulation of
the meningeal nerve terminal and the third chemical
stimulation of meningeal afferent nerve terminals (see
Administration of inflammatory substances to the men-
inges in-vivo section).
Firstly, the trigeminal ganglion of anesthetized animals
can be electrically stimulated using inserted stereotactic bi-
polar electrodes. Trigeminal ganglion neurons are then ac-
tivated using low frequency ( ̴ 5-Hz) stimulation [41–43].
The benefit of this model is that tissue specific changes in
the meninges and activation of central neurons and their
response to drug therapy can be examined more directly as
compared to in-vitro models. For example, data from this
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model has demonstrated that trigeminal ganglion stimula-
tion causes release of CGRP from perivascular afferent ter-
minals innervating the meninges. This release was
accompanied by triptan sensitive ultrastructural morpho-
metric changes in the neuropeptide containing nerve ter-
minal swellings [41, 42]. While trigeminal ganglion
electrical stimulation also produces activation of neurons in
the trigeminal nucleus caudalis (as measured by expression
of immediate early genes; see Immunohistochemistry sec-
tion), this activation was not modulated by administration
of sumatriptan [42]. While certain studies utilized pro-
longed stimulation paradigms (approximately 30min) that
may be considered supramaximal to induce morphological
changes, shorter ganglionic stimulation (3–5min) protocols
also elicit peripheral neuropeptide release that is responsive
to the triptans and dihydroergotamine [44]. The ability to
target the trigeminal ganglion directly has many advantages,
given its key role in the pathophysiology of migraine-
related pain. Importantly, evidence using this approach sup-
port triptan and dihydroergotamine induced inhibition of
peripheral neuropeptide release as a plausible mechanism
of anti-nociceptive action [44]. However, the need to insert
stimulating electrodes deep into the brain parenchyma has
the potential to generate inflammatory responses both lo-
cally on the dura mater and throughout the central nervous
regions traversed by the electrodes.
Secondly, similar to stimulation of the trigeminal gan-
glion, electrical stimulation of meningeal nerve terminals
innervating the superior sagittal sinus [15], transverse
sinus [45] or middle meningeal arteries [46, 47] to elicit
trigeminal afferent activation have also been used to
model migraine preclinically. These approaches evolved
from the demonstration in humans: that their stimula-
tion was considered painful and that this pain was often
referred to the face [12] and that their stimulation in
cats produced similar alterations in neuropeptide release
to migraine patients [13, 15]. Moreover, direct stimula-
tion of the intracranial vessels and subsequent activation
of the meningeal afferents that innervate them, leads to
the polysynaptic activation of the central projection sites
of these afferents in the trigeminal nucleus caudalis and
ascending projections throughout the central nervous
system [48–51]. Such studies have proven critical in the
ability to identify specific migraine-related pain process-
ing nuclei throughout the brain. Furthermore, direct
stimulation of nerve terminals innervating the intracra-
nial vasculature and their meningeal afferents has proven
a robust model to test differential responses to drug ad-
ministration [45–47, 52, 53], similar to direct stimulation
of the trigeminal ganglion as mentioned above [54, 55].
Importantly, this pharmacological testing has proven to
be highly predictive of translational efficacy, both in
terms of positive translation [46, 56, 57], therapeutic
potential [58] and clinical trial failure [59], highlighting
their continued utility. While in-vivo electrical stimula-
tion models better account for the biological complexity
of disease as compared to in-vitro models, they are lim-
ited by the invasiveness of craniotomy and tissue expos-
ure. Additionally, upstream events leading to trigeminal
activation are bypassed and stimulation parameters must
be carefully regulated to prevent supramaximal stimula-
tion that may not adequately represent a physiological
state [18]. Animals are anesthetized and therefore differ-
ent anesthetic regimes need to be considered. Lastly,
while these models represent surrogate readouts of tri-
geminal nociceptive activation at the specific recording
site, they do not incorporate many aspects of pain, or
determine the overall pain phenotype at the whole ani-
mal level.
Administration of inflammatory substances to the
meninges in-vivo
Several experimental approaches use dural application of
algogenic substances to model the proposed meningeal
neurogenic inflammation thought to initiate migraine-
related pain via trigeminovascular afferent and central
neuronal sensitization [60, 61]. Inflammatory substances
can be applied to the dura singly or in combination as
an inflammatory soup. Commonly used substances
include histamine, serotonin, bradykinin and prostaglan-
din E2. Other substances including capscaisin, low or
high pH buffered solutions [62], cytokines [63] and
complete Freund’s adjuvant [64, 65] have also been used.
The application of these substances has been used to
examine peripheral and central neuronal sensitization
to various stimuli. Meningeal exposure to the above
mentioned inflammatory substances alone or a combin-
ation as an inflammatory soup has been used as a
reliable method of activating and sensitizing trigemino-
vascular meningeal afferents in-vivo as measured by en-
hanced trigeminal ganglion responses to mechanical
stimulation of the meninges [61]. Meningeal application
of this inflammatory soup also produces activation and
sensitization of central neurons in the trigeminal
nucleus with convergent dural and cutaneous receptive
fields [60].
Over time, advancements in this model generated al-
ternate delivery methods, requiring less invasive proce-
dures that are now amenable to behavioral testing.
While sensitivity of trigeminal ganglion and trigeminal
nucleus caudalis neurons to mechanical stimulation fol-
lowing inflammatory soup infusion suggests heightened
trigeminal nociception, assessment of conscious pain re-
lated reflexes in the animal offers an additional method-
ology for determining changes in pain perception.
Response to mechanical stimulation using von Frey
monofilament testing of the periorbital region in the
awake behaving animal was therefore a critical evolution
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of the migraine pain model (see Behavior section). To
permit behavioral testing in response to chemical dural
stimulation, various models have been developed to
allow for administration of substances in conscious be-
having animals [66–69]. Repetitive inflammatory soup
administration induces a chronic periorbital hypersensi-
tivity to tactile stimuli that lasted for up to 3 weeks, sug-
gestive of a model of chronic migraine [70]. In selecting
this model, the researcher must consider that upstream
events leading to trigeminal activation are bypassed and
the chemical cocktail utilized requires careful control to
prevent supramaximal stimulation. The surgical proce-
dures, while improved, are intricate and could result in
mast cell degranulation around the insertion site of the
catheter.
Exogenous administration of algogenic substances in-vivo
A key feature of migraine is that various triggers can ini-
tiate an attack and experimentally, chemical triggers
have been used extensively in human models of migraine
[71, 72]. Nitric oxide donors, including nitroglycerin,
have emerged as the most prominent exogenous algo-
genic substances to date. This is based on early observa-
tions of their headache producing qualities in angina
patients and during occupational exposure [73, 74].
However, more recently CGRP, PACAP and cilostazol have
all emerged as viable human migraine triggers [75–77] and
have been reverse translated into preclinical models of mi-
graine pain [52, 58, 78, 79].
Importantly from a translational aspect, it is now be-
coming evident that such exogenous algogenic sub-
stances also trigger other migraine-related features in
conjunction with pain responses. For example, both
nitroglycerin and PACAP, but not CGRP, trigger mi-
graine premonitory symptoms in patients [80–82] and
nitroglycerin triggers cranial allodynia [52]. Recent pre-
clinical studies have identified several pain-related and
non-pain phenotypes following their administration and
their utility is further enhanced by the ability to study
both acute administration and a more chronic regime,
considered relevant to migraine chronification [83].
The selection of a specific algogenic agent is
dependent on the individual study requirements. Nitro-
glycerin and related nitric oxide donors have been used
both in combination with in-vivo electrophysiological
models where they induce a latent sensitization of tri-
geminal sensory afferents [52], and in freely behaving
models where they induce increased activation of the
trigeminovascular system and both periorbital and
hindpaw hypersensitivity to tactile and thermal stimuli
[84, 85]. As an alternate, based on the developing thera-
peutic potential of inhibiting CGRP signaling [8], the
use of CGRP preclinically is increasing. Originally used
in models of neurogenic dural vasodilation that
explored therapeutic interventions on peripheral neuro-
vascular CGRP signaling at the level of the dura mater
[86, 87], more recently CGRP has been shown to trigger
photophobia, periorbital hypersensitivity and spontan-
eous pain behaviours in rodents [79, 88, 89]. Further-
more, PACAP has shown preclinical potential. In the
hemisected skull model, PACAP-38, but not PACAP-27
induced mast cell degranulation [90], while in-vivo studies
demonstrate a delayed sensitization of trigeminovascular
nociceptive processing [58] following PACAP infusion in
rodents.
The use of algogenic, or migraine triggering agents in
preclinical models of migraine-related pain has many ad-
vantages as well as important limitations to consider.
The use of specific migraine triggering agents is
strengthened by the specificity of such triggers, whereby
alternate related molecules including vasoactive intes-
tinal peptide (VIP), amylin or adrenomedullin, fail to in-
duce pain behaviours or periorbital hypersensitivity in
mice [88]. Importantly, exogenous algogenic substances
are not restricted to specific peripheral or central ner-
vous system sites and as such, have the potential to act
more generally in migraine-relevant structures. This has
clear advantages for disease modelling with the induc-
tion of premonitory symptoms in patients [80–82], how-
ever, it raises several unanswered questions regarding
potential sites and mechanisms of action that need to be
determined to fully appreciate their potential. Further,
specific dosing regimens need to be adopted to allow a
more thorough comparison between studies. For ex-
ample, wild-type mice classically respond to a dose of
10 mg/kg of nitroglycerin, whereas mice harbouring gen-
etic mutations linked to migraine with aura have been
shown to respond to much lower doses [85]. Finally,
such models have the potential to explore both acute re-
sponses and a more chronic state in rodents. Repetitive
dosing over time has the potential to produce a pro-
longed basal hyperalgesia [83], however, such responses
are also observed during chronic exposure to acute anti-
migraine therapeutic agents [91], highlighting the com-
plexity of determining divergent or shared downstream
signaling cascades that may represent key targets for
migraine.
Experimental readouts: electrophysiology and
immunohistochemistry
Electrophysiology
As detailed previously, the activation of meningeal affer-
ents that innervate the dural blood vessels, including the
middle meningeal artery and the superior sagittal and
transverse sinuses, results in headache pain that is very
similar to the migrainous pain [12, 92]. Therefore, acti-
vation of the trigeminovascular system has consistently
been used as a model of migraine-related pain. The
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trigeminovascular system includes the trigeminal gan-
glion, that sends primary sensory afferents to intra- and
extracranial structures [93], including the dural blood
vessels, and central projections to the trigeminal nucleus
caudalis and the associated first and second cervical
levels [94]. Second order neurons project from the tri-
geminal nucleus caudalis to higher order structures in
the brainstem and diencephalic nuclei involved in pain
processing [95–97]. As noted, several paradigms have
been developed to facilitate the activation of the trigemi-
novascular system in-vivo and targeted electrode place-
ment has facilitated the recording of durovascular
evoked responses throughout the central nervous sys-
tem. Given the importance of the meningeal afferents
and their central synapses on the trigeminal nucleus
caudalis, it is not surprising that the trigeminal nucleus
caudalis has received considerable attention with respect
to targeted neuronal activity recordings.
Electrophysiological recordings of trigeminal nucleus
caudalis neuronal responses to nociceptive durovascular
stimulation have been widely used as a readout of noci-
ceptive trigeminovascular activation [45, 46, 98, 99]. The
nature of the recordings from within the spinal cord
dorsal horn necessitate the use of a laminectomy of the
first cervical vertebrae along with an incision of the dura
mater. Recording electrode placement is largely opti-
mized via the mapping of cutaneous and dural receptive
field responses, and once the appropriate level is located,
specific cell types can be identified [18]. Second order
trigeminothalamic projection neurons receive the major-
ity of their inputs from thinly myelinated Aδ- and unmy-
elinated C-fibres [60, 100–103] arising in the trigeminal
ganglion. As such, both fiber latency responses can be
recorded and analyzed differentially to determine spe-
cific effects [104]. In addition to the specific A and C-
fiber latencies, a variety of neuronal subtypes can be
identified using high impedance electrodes that allow for
single-cell responses to be recorded. The three major
classes include low-threshold mechanoreceptors
responding to innocuous stimulation, wide dynamic
range neurons responding to both noxious and non-
noxious stimuli, or nociceptive specific neurons that
only respond to noxious input [105]. In addition to the
trigeminal nucleus caudalis, in-vivo electrophysiology
has the potential to map neuronal alterations in several
migraine-relevant nuclei, with the thalamus also receiv-
ing considerable attention [106, 107] highlighting poten-
tial therapeutic benefits of modulating thalamocortical
signaling.
In addition to the ability to target specific nuclei
throughout the brain, direct trigeminal nucleus caudalis
recording is commonly combined with alternate meth-
odologies, including microinjection in discrete brain
areas to discern functional connections. By combining
these methodologies several modulatory networks regu-
lating trigeminal nucleus caudalis durovascular evoked
responses have been identified, including the A11 [108],
the locus coeruleus [47], the ventrolateral periaqueductal
gray [109, 110], thalamic [57] and hypothalamic [45] nu-
clei. Additionally, in seminal studies exploring the im-
pact of environmental stimuli, potential mechanisms
underlying light-induced exacerbation of durovascular
nociceptive processing were identified in the posterior
thalamus [111].
This in-vivo model has proven highly predictive in
the pharmacological screening of potential anti-
migraine compounds. Experimental pharmacological
evidence has shown that effective treatments such as
triptans [112–114], CGRP antibodies [104, 115],
gepants [116], lasmiditan [117] and vagal nerve stimu-
lation [118] all demonstrated significant efficacy; com-
pounds that have failed clinical trials such as
neurokinin 1 receptor antagonists do not [59].
A particular method to characterize the pharmacology
of neuronal responses is the use of in-vivo electrophysi-
ology in combination with microiontophoresis [119]. In
this setup, a multi-barrel electrode, that includes a re-
cording electrode and several capillaries, is used to
pharmacologically modulate the neurons, that at the
same time are being recorded by using the flow of elec-
tric charge through an aqueous solution to eject drugs
to a small number of cells. Microiontophoretic ejection
of ergot alkaloids [120] and triptans [121–123] in the tri-
geminal nucleus caudalis has been shown to inhibit
nociceptive durovascular and local glutamate-evoked re-
sponses indicating a potential central action of these
compounds. Interestingly, the later glutamatergic based
direct activation may allow for a degree of site specificity
to be defined, as the exogenous glutamate likely acts on
postsynaptic receptors and thus an ability to selectively
block this response would suggest a postsynaptic effect
on trigeminothalamic projection neurons and not a
direct effect on incoming meningeal afferents. This ap-
proach has identified potential central sites of action for
several anti-migraine therapeutic targets including the
CGRP receptor antagonist olcegepant [124] and the 5-
HT1B/1D receptor agonist naratriptan [107]. While the
ability to determine potential local action of specific
compounds is an advantage, it relies on bypassing the
blood brain barrier that remains a significant barrier to
the clinical development of central nervous system
targets.
The use of in-vivo electrophysiology has several advan-
tages, not least of which is the flexibility of methodolo-
gies to activate the underlying pathways of interest,
including specific dural evoked responses and those elic-
ited following the administration of exogenous algogenic
substances. However, great care must be taken during
Harriott et al. The Journal of Headache and Pain           (2019) 20:91 Page 6 of 15
surgical procedures and while modeling migraine-related
pain in an intact nervous system with complex interfaces
between the peripheral and central compartments is an
advantage, the invasive nature of the surgery and subse-
quent disruption of the blood brain barrier must be
carefully controlled for. Finally, current in-vivo electro-
physiological procedures are largely acute in nature and
therefore preclude longitudinal studies; future research
should and most likely will take advantage of the in-
creasing trend to conduct such studies in conscious be-
having animals [125].
Immunohistochemistry
C-Fos immunoreactivity
A complementary or alternate method to in-vivo models
of migraine-related pain is the identification of neuronal
activation in key nociceptive processing structures such
as the trigeminal nucleus caudalis using markers of
neuronal activation, mainly c-Fos immunoreactivity
[126]. The gene FOS is an immediate early gene that en-
codes the proto-oncogene c-Fos, which dimerizes with
transcription factors of the Jun family to build up the
transcription factor AP-1 regulating the expression of
downstream target genes [127]. In neurons, c-Fos ex-
pression can be stimulated by at least 3 second-
messengers, including cAMP, protein kinase C and
calcium-calmodulin, through the activation of the
CREB/Cre complex [128]. c-Fos expression can be de-
tected from 30min to an hour after intense stimuli,
reaching its peak at 2-4 h and returns to basal levels 8-
24 h following stimulation [129]. Most commonly, c-Fos
expression is visualized via the immunohistochemical
detection of c-Fos in the nuceli of cell bodies [130].
c-Fos was one of the first transcription factors whose
induction was shown to be activity-dependent [131].
Early studies identified that c-Fos is induced in the
spinal dorsal horn following peripheral noxious stimula-
tion [132], leading to its widespread use to study noci-
ception [133]. In migraine-related pain research, c-Fos
expression is commonly used as a valuable tool to iden-
tify subpopulations of neurons activated in response to
noxious stimuli and related nociceptive pathways [19].
Hence, many studies have used c-Fos immunoreactivity
to map neuronal activation throughout the trigemino-
vascular system, which has helped to generate a greater
understanding of migraine pathophysiology [49, 113,
134–136]. Electrical, mechanical and chemical stimula-
tion of meningeal afferents and systemic administration
of algogenic substances including nitroglycerin induce c-
Fos expression in the nociceptive-specific laminae of the
trigeminal nucleus caudalis [49, 134, 137–139], which
can be inhibited by anti-migraine treatments such as
triptans [55, 84, 99, 140, 141], dihydroergotamine [99]
and lasmiditan [142]. Thanks to the ability of c-Fos to
respond to polysynaptic activation, this method also
allows functional pathways to be mapped and therefore
to determine ascending and descending pathways in-
volved in migraine pathophysiology. To this end, c-Fos
expression has been mapped in several brainstem struc-
tures, including the PAG [143–145], parabrachial
nucleus and locus coeruleus [145]. Higher order di-
encephalic nuclei including the hypothalamus (e.g. the
ventromedial nucleus, the supraoptic nucleus and the
posterior hypothalamus [48, 51]) and thalamus (e.g. the
thalamic reticular and centromedian nuclei [146, 147]).
The use of c-Fos expression has facilitated stepwise
changes in our understanding of the pathophysiology
of migraine and migraine-related pain. However, re-
searchers must be wary of specific limitations, includ-
ing the stimulus used to drive its expression [19].
This limitation is shown by the failure of substance
P-neurokinin-1 receptor antagonists in acute and pre-
ventive treatment of migraine [148], although they
have been shown to block c-Fos expression in the tri-
geminal nucleus caudalis following trigeminal ganglion
stimulation [141, 149]. Importantly, the lack of c-Fos
expression does not guarantee the absence of neur-
onal activation, as not all activated neurons express c-
Fos, including those in the dorsal root ganglia [132].
Another important consideration is that the induction
of quantifiable levels of c-Fos requires a strong con-
sistent stimulation that is not usually physiologically
relevant.
Alternative markers of neuronal activation
In certain conditions and with respect to specific tissues
that do not express c-Fos, alternate markers of neuronal
activation can prove beneficial. The extracellular signal-
regulated kinase (ERK) is a member of the mitogen-
activated protein kinase family. Once activated, phos-
phorylated ERK (pERK) is translocated into the nucleus
where it activates several transcription factor s [150].
Like c-Fos, pERK expression [151] is very robust,
requires high-threshold noxious stimuli and can be
inhibited by analgesics. Unlike c-Fos, pERK expression is
faster and more dynamic, it cannot be induced by in-
nocuous stimuli and it is found in most subtype of neu-
rons, including dorsal root ganglia neurons [152], as it is
summarized in Table 1.
Experimental readouts: behavioral assays
Measuring pain-like behaviours in awake, freely-
behaving animals can provide key insights into the com-
plex and integrative systems underlying migraine-like
pain. An advantage of assessing pain-like behavior in
conscious animals is the ability to assess the impact of
experimental manipulations or therapeutic interventions
on the whole animal. However, in doing so, it is
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imperative that the experimenter is blinded to treat-
ments/experimental groups, as many behavioural assays
can be subjective and therefore vulnerable to uncon-
scious bias. When properly controlled, behavioural read-
outs are an invaluable tool for investigating migraine-
like pain phenotypes underlying migraine
pathophysiology.
Behavioural assays modeling migraine-like pheno-
types can exploit sensory discriminative/evoked pain-
like behaviors that focus on the trigeminal/spinal
reflexes, operant models that assess cognitive aspects
of pain, as well as spontaneous, non-evoked pain be-
havior. This section will focus on sensory discrimina-
tive readouts, as they are the most common and
easily quantifiable, but will also touch briefly on other
pain-like models as well.
Modeling cutaneous allodynia
Sensory discriminative models in headache research tend
to exploit a common associated symptom of migraine:
cutaneous allodynia. Allodynia is defined as the percep-
tion of normal innocuous sensory stimuli as uncomfort-
able or painful. It has been reported that 70% of
migraineurs experience cephalic allodynia: referred pain
or sensitization around the head that is induced by the
activation of the trigeminal system during an attack
[153]; extracephalic allodynia in the arms and legs is
reported in more severe and chronic cases [154, 155]
and is likely attributed to sensitization of third order tri-
geminal neurons in the thalamus [153, 156]. As such,
measurements of mechanical and thermal sensory noci-
ceptive thresholds as a readout of cutaneous allodynia
can be a reliable marker for migraine pathophysiology.
Mechanical allodynia
The most commonly used behavioural assessment of
pain-like behavior in preclinical headache models is
mechanical allodynia. Mechanical, or tactile, sensitivity is
easily quantified by using calibrated von Frey filaments.
These filaments are typically applied to the cephalic
(whisker pad or periorbital areas) or extracephalic (hind
paw) regions to determine evoked response thresholds.
There are three widely used methods for how to apply
the filaments and calculate a withdrawal response: the
up-down method, ascending stimulus, and percent re-
sponse rate. The up-down method calculates the thresh-
old to illicit a response in 50% of the animals based on a
statistical formula [157, 158]. This method involves ap-
plying the filaments in a pattern based on the animal’s
response to the previous filament. If there was a positive
response, the next filament applied would be the next
one of less force; if there was a negative response, the
next filament applied would be the one of next highest
force. This would be repeated for five applications from
the first positive response and a 50% mechanical with-
drawal threshold calculated [157]. The ascending stimu-
lus method sees filaments applied with increasing force
until a withdrawal response is evoked and the force of
this filament is recorded as the mechanical withdrawal
threshold [159]. Percent response sees filaments of vary-
ing forces applied in ascending order 5–10 times and
the number of positive responses to each filament are
recorded and the percent response calculated [157, 160].
In preclinical headache research, allodynia is often
assessed in response to dural inflammatory soup applica-
tion or the administration of algogenic substances. As dis-
cussed previously, the most common and well established
experimental migraine trigger is nitroglycerin. Preclinical
studies commonly use nitroglycerin to sensitize the trigemi-
novascular system and a single dose (1-15mg/kg) is known
to induce mechanical allodynia that can last up to 4 h in ro-
dents [83, 84, 88]. This increased sensitivity is therapeutic-
ally responsive to triptans [83, 84] and therefore
strengthens this as a model of migraine-related pain. Pre-
clinical investigations can thus utilize acute nitroglycerin
administration to assess allodynia, investigate underlying
mechanisms, or assess the efficacy of novel treatment tar-
gets by determining their ability to rescue nitroglycerin in-
duced pain-related phenotypes. Transgenic mice, harboring
a human mutation in casein-kinsase 1 delta, which is in-
volved in regulating the molecular biological clock and has
been linked to migraine in humans, have been shown to
have altered hind paw mechanical sensitivity in response to
nitroglycerin compared to controls [85]. As such, specific
migraine-relevant genetic mutations appear to increase the
sensitivity to nitroglycerin, which is in contrast to the previ-
ously identified inability of nitroglycerin to trigger attacks
in familial hemiplegic migraine patients [161].
Table 1 Comparison of several features of c-Fos and pERK
expression (Adapted from [152]). IHC, immunohistochemistry
c-Fos pERK
Methods of detection IHC IHC
Mechanism of detection Gene
expression
Phosphorylation
Induction by noxious
stimuli
Yes Yes
Induction by innocuous
stimuli
Sometimes No
Stimulus intensity-
dependent
Yes Yes
Subcellular distribution
in neurons
Nucleus Nucleus, cytoplasm,
dendrites, axons
Time course after formalin injection
Onset 30 min-1 h 1-3 min
Peak induction 1-2 h 2-10 min
Return to base 8-24 h 1-2 h
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In addition to acute behavioural responses, repeated ad-
ministration of nitroglycerin regimens have been estab-
lished in order to assess biological mechanisms involved in
migraine chronification. By repeated dosing, every other
day for 9 days, a progressive and sustained basal hypersensi-
tivity is observed in addition to the acute post treatment re-
sponses [83]. This basal hypersensitivity can be blocked by
migraine preventives such as topiramate and propranolol
[83, 162], supporting this as a model of chronic migraine
and therefore be used to test novel anti-migraine preventa-
tives. For example, ghrelin has been shown to attenuate
nitroglycerin induced nociception by rescuing mechanical
sensitivity, thus providing evidence that ghrelin has a
modulating effect on central sensitization [163]. The basal
hypersensitivity induced following chronic nitroglycerin is
accompanied by increased CGRP expression in central
brain areas with possible interaction with GABA and glu-
tamate transmission that may contribute to the induction
and maintenance of central sensitization [164]. Further-
more, direct stimulation of the nitric oxide receptor soluble
guanylyl cyclase can chronically increase basal hypersensi-
tivity which is subsequently blocked by acute and preventa-
tive migraine medications such as triptans and topiramate,
thus indicating that nitroglycerin may in part cause
migraine-related pain through stimulation of this pathway
and that activation of this receptor may be an important
component for the maintenance of chronic migraine [165].
In addition to nitroglycerin, other migraine provoking
substances have been seen to elicit cephalic and extrace-
phalic allodynic responses in rodents. Acute administra-
tion of CGRP, PACAP, histamine and prostaglandin E2
were shown to elicit periorbital mechanical sensitivity,
which was attenuated by systemic antagonists [88]. Fur-
thermore, intrathecal injection of CGRP has also been
shown to induce hind paw mechanical allodynia in wild
type mice and this response was further enhanced in
transgenic mice that overexpress the CGRP receptor ac-
tivity modifying protein 1 [166].
Finally, mechanical allodynia has been seen in
response to trigeminal sensitization through other
models such as inflammatory soup and cortical
spreading depression. Application of inflammatory
mediators onto the dura mater in awake, freely moving
rats induces both facial and hind paw mechanical allo-
dynia [67, 68, 70, 167], which is reversed by sumatrip-
tan and CGRP receptor antagonist [67]. Cortical
spreading depression, the electrophysiological correl-
ate of migraine aura, can also activate trigeminal pain
pathways. Cortical spreading depression induced
mechanical allodynia has been observed in both the
face and the hind paws of rats following multiple events
[168]. Reduction in mechanical withdrawal thresholds ip-
silateral to the cortical spreading depression can be
reversed by a CGRP receptor antagonist [169].
Thermal allodynia
While most studies seem to assess mechanical allodynia,
thermal allodynia (both hot and cold) can also be
observed in preclinical models and can complement
mechanical sensitivity to further dissect underlying
mechanisms.
Cold sensitivity can be measured with ease in both
cephalic and extracephalic body regions using the acet-
one evaporation test. Here, nociceptive behaviors are in-
duced by the evaporative cooling of acetone on the skin
and such behaviours can be counted, timed or scored
[170, 171]. Assessing extracephalic thermal allodynia is
easily assessed using the Hargreaves or tail flick test.
The Hargreaves test involves directing a heat stimulus to
the animals hind paw and measuring the withdrawal la-
tency [172]. Additionally, a heat stimulus can be directed
to the animals tail and withdrawal latency recorded. The
heat stimulus can be in the form of an infrared beam or
hot water bath (48 ± 5 °C). Using the Hargreaves assay,
acute nitroglycerin [84] and chronic administration of algo-
genic substances increased thermal sensitivity [83, 165].
Furthermore, a different model of chronic migraine, nasoci-
lary nerve ligation in rats, exhibits a lateralized sensitization
to acetone following nitroglycerin in the forehead ipsilateral
of nerve ligation [173]. One important differentiation is that
behavioral studies have also shown differential response to
mechanical and thermal allodynia, highlighting the com-
plexity of trigeminal pain processing. For example, Brennan
et al. showed that a higher dose of nitroglycerin was re-
quired to elicit differences in thermal allodynic responses in
transgenic mice compared to a lower dose required for
mechanical sensation [85]. In addition, Kim et al. showed
differential mechanical and thermal sensitivities in the oro-
facial region and hind paw following chronic nitroglycerin
[174]. In this study, cold was assessed on the face via acet-
one, while heat on the paw, likely due to the difficulty to
direct a thermal stimulus to the orofacial region of an
awake, freely moving animal.
One way this can be overcome is by the use of a
novel operant behavioral assay using the orofacial
pain assessment device (OPAD). Here, animals are
trained to drink a reward while forced to place their
face through temperature controlled thermal pads.
Pain is assessed as a reduction in amount of reward
consumed (quantified by number of licks) as well as
contacts against the thermal pads [175, 176]. Recent
work has shown that nitroglycerin treatment can de-
crease the amount of licks/contacts in wild type mice
[177] indicating an increased sensitivity to thermal
orofacial stimulation.
Operant models for assessing cognitive aspects of pain
Operant pain assessment assays have been used in pre-
clinical headache research to assess emotional
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dysfunction and affective-motivational components of
pain. The advantage of operant based tests compared to
other evoked sensory discrimination tests is that it is
also a measure of higher order pain processing rather
than relying on spinal reflex-based nociception. The oro-
facial pain assessment device mentioned above is also a
readout of the emotional or motivational component of
pain in that the animal needs to choose between a re-
ward associated with a painful stimulus or forgoing the
reward in order to avoid the pain [175], which adds
translational value as it does not solely rely on the re-
flexive component of pain.
Another operant assay is the conditioned place
aversion test, which measures the amount of time
the animal spends in an area that has been associ-
ated with an aversive or painful stimulus. Chronic
nitroglycerin has been shown to induce place avoid-
ance, where animals learn to spend less time in the
chamber associated with nitroglycerin and thus the
painful experience. Novel therapeutic targets can
prevent the condition place aversion either through
analgesic effects or stimulating reward pathways
[163, 178].
Spontaneous pain behaviors
Spontaneous, or non-evoked behaviors can also be used
as alternative readouts of pain and can be more indica-
tive of headache-pain rather than the associated symp-
tom of allodynia. Spontaneous behaviors such as
exploration, locomotor activity, rearing or food and
water consumption are thought to be general measures
of a rodents overall wellbeing and can all decrease with
pain. Other behaviors, such as freezing and grooming
can increase and thus such behaviors can be measured
as indirect markers of a pain-like state [179]. In migraine
headache, activation of the trigeminovascular system can
lead to headache worsened by activity, so freezing in ro-
dents might reflect an activation of this system and a
defense mechanism to restrict movement exacerbation
of pain [169, 180]. Grooming reflects increased attention
to the affected area, which may infer pain or discomfort.
The above behaviors can be measured by observation or
through a behavioral analysis system applied to a stand-
ard cage that is able to detect and classify behavioral var-
iables based on vibrations produced by the movement of
the animals. In headache research, it has been shown
that cortical spreading depression can induce spontan-
eous pain behaviors such as freezing and grooming in
freely moving rats and mice [169, 180, 181] which can
subsequently be alleviated by a CGRP antagonist [169].
Additionally, trigeminal activation through the applica-
tion of inflammatory mediators has also been shown to
decrease activity and increase resting and grooming be-
havior which were then attenuated by a triptan [182].
Future perspectives
While the above-mentioned models have significantly
enhanced our understanding of migraine pathophysi-
ology, led to the development of novel therapies and
forged a path for future translational research in
migraine; there remains an ongoing requirement to re-
fine existing and generate novel models of migraine.
While not covered here, such models should explore not
only migraine-related pain, but attempt to explore alter-
nate migraine-related phenotypes to better recapitulate
the disorder as a whole.
Advanced genetic modelling
Improvements in genome wide analysis studies have led
to a wealth of data on polygenic risk factors for migraine
with approximately 40 genetic loci identified [183]. This
ever increasing list of risk factors is now combined with
several rarer monogenic mutations responsible for spe-
cific migraine phenotypes [85, 184–186]. With advances
in CRISPR/Cas9 technologies to facilitate gene editing in
mice [187], the migraine field now has the potential to
determine the specific impact of knocking in or out spe-
cific genes of interest. Such approaches have already
proven effective. For example, generation of transgenic
mice that overexpress the human receptor activity modi-
fying protein 1 essential for the canonical CGRP recep-
tor has facilitated several studies exploring CGRP
hypersensitivity. These transgenic mice demonstrate
clear nociceptive hypersensitivity to the algogenic sub-
stance CGRP combined with a photophobic phenotype
suggesting a potential role for increased CGRP in the
generation of photophobia [188, 189]. More recently a
novel circadian related mutation resulting in the loss of
function of casein kinase 1 delta and subsequent
PERIOD-mediated phase advancing of the circadian
clock has been identified [85]. In humans this mutation
results in a familial advanced sleep phase and an ex-
tremely high penetrance of migraine with aura. Gener-
ation of a transgenic mouse that harbors the human
mutation, enabled the identification of specific migraine
phenotypes including a reduced threshold for triggering
cortical spreading depression and an increased sensitivity
to the human migraine trigger and algogenic substance
nitroglycerin compared to wild type littermate mice.
Such studies have the potential to enhance our know-
ledge on the impact of genetic and genetic/environment
interaction’s on migraine susceptibility. In addition to
specific gene editing approaches, an inbred rat model of
spontaneous trigeminal allodynia has been described
that is responsive to acute and preventive migraine ther-
apies [190]. This model has recently been further inbred
to generate a sustained trigeminal hypersensitivity that is
responsive to acute migraine therapies with potential im-
plications for modelling chronic migraine [191].
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Advanced viral vector approaches
The neuroscience field has experienced a vast expan-
sion in the capability to selectively target specific
neuronal populations using viral vector approaches.
Such approaches allow for the targeted delivery and
transfection of neurons based on their neurotransmit-
ter profile, genetic makeup or anatomical distribution,
while alternate transgenic mouse lines have been gen-
erated that specifically express chemogenetic and
optogenetic constructs. While the use of such tools is
in its infancy in migraine research, several studies
have emerged that show the potential of such meth-
odologies. For example, as discussed above, many
current methods to activate the trigeminovascular sys-
tem involve invasive cannula or electrode placement
with potential impacts on cerebrovascular physiology.
In a seminal study in the field, Houben et al. used
optogenetic stimulation to activate channelrhodopsin-
2 ion channels resulting in the activation of layer 5
cortical neurons and the subsequent induction of cor-
tical spreading depression [192]. While this study pri-
marily focused on the cortical spreading depression, it
is appreciated that cortical spreading depression can
act as a trigger to activate the trigeminovascular sys-
tem [193] that is responsive to preventative migraine
therapies [115] and trigger pain-related responses in
rodents. As such, the combination of novel targeted
optogenetic or chemogenetic approaches to evoke
migraine-related pain and associated phenotypes in
rodents holds enormous potential for the field. This
approach is further enhanced by the ability to map
detailed neuronal projections throughout the nervous
system. More general tracing technologies have
already been used to great effect in preclinical models
of migraine-related pain including the exploration of
pain processing pathways and potential photophobic
and autonomic responses to light [194–197]. By util-
izing novel tracing technologies that allow unrivaled
precision down to the level of the single monosynap-
tic inputs on a specific cell type [198] the potential to
map as yet unappreciated functional migraine-relevant
brain networks holds significant potential.
Conclusion
Our understanding of migraine-related pain processing
and the development of novel therapeutics for its modu-
lation has evolved via key translational research streams
in humans and experimental animals. Herein, we have
largely focused on the most commonly used preclinical
models of migraine-related pain; however, despite sig-
nificant success, there remains a major unmet need to
generate novel knowledge on the underlying mecha-
nisms of migraine initiation, associated symptoms and
ultimately attack cessation. Future preclinical research is
a necessity to achieve this goal, and while alternate read-
outs that can help to reduce the use of animals in
research are encouraged, for now the whole animal is
the only model that can accurately examine the complex
interactions between the peripheral and central nervous
systems. As such, it is essential that researchers continue
to refine existing and develop novel models to enable
studies that explore the diverse symptomatology of mi-
graine, while continuing to achieve significant transla-
tional success in terms of novel disease modifying
therapies.
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